Feature | August 23, 2012

Generic Clopidogrel Will Contract U.S. Market, Before the Uptake of Novel Agents Increases

In PCI-treated patients in the acute setting, increasing use Angiomax and otamixaban will expand the market over the next decade

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially contract from just under $2 billion in 2011 to about $1.6 billion in 2013, mainly as a result of the U.S. genericization of clopidogrel (Bristol-Myers Squibb/Sanofi’s Plavix) in 2012. Decision Resources forecasts that the post-hospital acute coronary syndrome antiplatelet/anticoagulant market will then expand to almost $2.7 billion in 2021, owing largely to uptake of oral agents with novel modes of action, such as AstraZeneca’s ticagrelor (Brilinta) and the CETP inhibitors, Merck’s anacetrapib and Eli Lilly’s evacetrapib.

“We expect anacetrapib to be the first CETP inhibitor to launch for acute coronary syndrome in 2018, followed by evacetrapib in 2019,” said Decision Resources Analyst Conor Walsh, Ph.D. “We anticipate that these agents will demonstrate significant reductions in cardiovascular events in their Phase III trials, mainly driven by their highly effective LDL-C-lowering abilities. As a result, sales of this drug class are forecast to be $578 million in 2021 in the 12-month post-hospital setting, equivalent to about one-fifth of total sales in this market.”

The Pharmacor advisory service entitled Acute Coronary Syndrome also finds that ticagrelor — approved in Europe in 2010 and in the United States in 2011 — is the drug most likely to change medical practice in acute coronary syndrome. In a Phase III clinical trial, this ADP receptor antagonist significantly reduced the risk of mortality compared with clopidogrel, which has been a mainstay of therapy for the indication.

“In 2021, despite a slow start, we forecast that ticagrelor will earn major-market sales in excess of $650 million for acute coronary syndrome treatment up to 12 months,” Walsh said.

The findings also reveal that, in patients being treated for percutaneous coronary intervention, higher-priced anticoagulants such as The Medicines Company’s bivalirudin (Angiomax)  and Sanofi’s emerging factor Xa antagonist otamixaban will gradually capture share, at the expense of unfractionated heparin. This trend will partly offset the sales decline in this class due to the genericization of Sanofi’s Lovenox/Clexane.

Also, in the acute setting, generic erosion of the glycoprotein (gp) IIb/IIIa inhibitor eptifibatide (Merck/GlaxoSmithKline’s Integrilin) and a general reduction in the use of drugs from this class will be responsible for a drop in market value in excess of $150 million through 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

For more information: www.decisionresources.com

 

Related Content

News | Business| February 09, 2016
February 9, 2016 — Cigna has entered into an...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
Watchman, left atrial appendage closure, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| February 09, 2016
February 9, 2016 — Boston Scientific Corp.
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
Overlay Init